Creative Medical Technology Holdings Inc 2026年季度报告

FORM 10-Q(Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-53500 Creative Medical Technology Holdings, Inc.(Exact name of Registrant as specified in its charter) 87-0622284(I.R.S. EmployerIdentification No.) 85012(Zip Code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 duringthe preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirementsfor the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ As of May 1, 2026, there were 3,696,668 shares of the registrant’s common stock outstanding. Item 1.Financial StatementsUnaudited Condensed Consolidated Balance Sheets3Unaudited Condensed Consolidated Statements of Operations4Unaudited Condensed Consolidated Statements of Cash Flows5Unaudited Condensed Consolidated Statements of Stockholder’ Equity6Notes to Unaudited Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk24Item 4.Controls and Procedures24PART II – OTHER INFORMATIONItem 1.Legal Proceedings25Item 6.Exhibits26 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS STOCKHOLDERS' EQUITYPreferred stock, $0.001 par value, 10,000,000 shares authorized at March 31, 2026 and December 31, 2025--Common stock, $0.001 par value, 25,000,000 shares authorized; 3,701,668 issued and 3,696,668 outstanding at March31, 2026 and December 31, 2025, respectively3,1443,144Additional paid-in capital78,108,42278,108,422Accumulated deficit(71,991,998)(70,586,921)Treasury stock, at cost, 5,000 shares as of March 31, 2026 and December 31, 2025.(10,000)(10,000)TOTAL STOCKHOLDERS' EQUITY6,109,5687,514,645Non-controlling interest23,36010,000TOTAL EQUITY ATTRIBUTABLE TO CMTH6,132,9287,524,645TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$6,440,577$7,809,525 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Issuance of note receivable(50,000)-Investment in related entity(125,000)-Net cashusedin investing activities(175,000)- Contribution from minority member13,360-Purchase of treasury stock-(10,000)Proceeds from sale of common stock and warrants, net of issuance costs-3,364,000Net cashprovidedin financingactivities13,3603,354,000 NET CHANGE IN CASH(1,484,950)1,762,465BEGINNING CASH BALANCE7,208,1265,940,402ENDING CASH BALANCE$5,723,176$7,702,867 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSMARCH 31, 2026 NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization- Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company dedicated to the advancementof regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company was incorporated on December 3,1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as arecapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly ownedsubsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s